JP2009511034A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009511034A5 JP2009511034A5 JP2008535031A JP2008535031A JP2009511034A5 JP 2009511034 A5 JP2009511034 A5 JP 2009511034A5 JP 2008535031 A JP2008535031 A JP 2008535031A JP 2008535031 A JP2008535031 A JP 2008535031A JP 2009511034 A5 JP2009511034 A5 JP 2009511034A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- nucleotides
- independently selected
- integer
- uuu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 35
- 239000002773 nucleotide Substances 0.000 claims 22
- 125000003729 nucleotide group Chemical group 0.000 claims 22
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 10
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 8
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 229940035893 uracil Drugs 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 3
- 229940045145 uridine Drugs 0.000 claims 3
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 2
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 2
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 229920002873 Polyethylenimine Polymers 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000036737 immune function Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940124589 immunosuppressive drug Drugs 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72630505P | 2005-10-12 | 2005-10-12 | |
| US75191705P | 2005-12-20 | 2005-12-20 | |
| PCT/EP2006/067334 WO2007042554A2 (en) | 2005-10-12 | 2006-10-12 | Methods and compositions for treating immune disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009511034A JP2009511034A (ja) | 2009-03-19 |
| JP2009511034A5 true JP2009511034A5 (enExample) | 2009-11-26 |
Family
ID=37770873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008535031A Pending JP2009511034A (ja) | 2005-10-12 | 2006-10-12 | 免疫異常を治療するための方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20090169472A1 (enExample) |
| EP (1) | EP1937812A2 (enExample) |
| JP (1) | JP2009511034A (enExample) |
| KR (1) | KR20080065656A (enExample) |
| AU (1) | AU2006301230A1 (enExample) |
| BR (1) | BRPI0617254A2 (enExample) |
| CA (1) | CA2625488A1 (enExample) |
| EA (1) | EA200801045A1 (enExample) |
| WO (1) | WO2007042554A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| WO2007062107A2 (en) | 2005-11-25 | 2007-05-31 | Coley Pharmaceutical Gmbh | Immunostimulatory oligoribonucleotides |
| DK2347775T3 (da) | 2005-12-13 | 2020-07-13 | Harvard College | Skabeloner til celletransplantation |
| US7985538B2 (en) | 2006-02-23 | 2011-07-26 | Yale University | Drug resistance and methods of reversing |
| DE102006035618A1 (de) * | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz |
| JP2010507361A (ja) | 2006-07-31 | 2010-03-11 | キュアバック ゲーエムベーハー | 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸 |
| AU2007287430B2 (en) * | 2006-08-23 | 2011-07-21 | Kudos Pharmaceuticals Limited | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors |
| CN101541965A (zh) * | 2006-09-27 | 2009-09-23 | 科勒制药集团股份有限公司 | Tlr配体与抗病毒剂的组合物 |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| US8349812B2 (en) * | 2007-11-06 | 2013-01-08 | Adiutide Pharmaceuticals Gmbh | Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties |
| MX2010008468A (es) | 2008-01-31 | 2010-08-30 | Curevac Gmbh | Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante. |
| US10328133B2 (en) | 2008-02-13 | 2019-06-25 | President And Fellows Of Harvard College | Continuous cell programming devices |
| WO2010020590A1 (en) * | 2008-08-20 | 2010-02-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8 |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| CA2801523C (en) | 2010-07-30 | 2021-08-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| CN107648668B (zh) | 2010-10-06 | 2021-06-18 | 哈佛学院董事会 | 用于基于材料的细胞疗法的可注射的成孔水凝胶 |
| GB201021867D0 (en) | 2010-12-23 | 2011-02-02 | Mologen Ag | Non-coding immunomodulatory DNA construct |
| US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| CN104244929B (zh) | 2012-04-16 | 2017-04-05 | 哈佛学院董事会 | 用于调节免疫反应的介孔二氧化硅组合物 |
| US9228184B2 (en) | 2012-09-29 | 2016-01-05 | Dynavax Technologies Corporation | Human toll-like receptor inhibitors and methods of use thereof |
| US9868955B2 (en) | 2012-09-29 | 2018-01-16 | Dynavax Technologies Corporation | Human toll-like receptor inhibitors and methods of use thereof |
| KR101441415B1 (ko) * | 2013-03-11 | 2014-09-24 | 국방과학연구소 | 신규한 ｓｉＲＮＡ, 이를 이용한 오소폭스바이러스에 대한 항바이러스 조성물 |
| ES2747762T3 (es) | 2013-08-21 | 2020-03-11 | Curevac Ag | Vacuna contra el virus respiratorio sincitial (RSV) |
| WO2015149944A2 (en) | 2014-04-01 | 2015-10-08 | Curevac Gmbh | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| US10682400B2 (en) | 2014-04-30 | 2020-06-16 | President And Fellows Of Harvard College | Combination vaccine devices and methods of killing cancer cells |
| KR101643947B1 (ko) * | 2014-06-27 | 2016-07-29 | 건국대학교 산학협력단 | gHA1 단백질에 특이적으로 결합하는 RNA 앱타머 및 그를 포함하는 약학 조성물 |
| EP3250250A4 (en) | 2015-01-30 | 2019-05-22 | President and Fellows of Harvard College | PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY |
| JP7094533B2 (ja) | 2015-04-10 | 2022-07-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 免疫細胞捕捉デバイスおよびその製造および使用方法 |
| LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
| GB2542425A (en) | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
| EP3411475B1 (en) | 2016-02-06 | 2025-08-27 | President and Fellows of Harvard College | Recapitulating the hematopoietic niche to reconstitute immunity |
| CN115537372A (zh) | 2016-07-13 | 2022-12-30 | 哈佛学院院长等 | 抗原呈递细胞模拟支架及其制备和使用方法 |
| EP3493842A4 (en) | 2016-08-02 | 2020-07-29 | President and Fellows of Harvard College | BIOMATERIALS TO MODULATE IMMUNE RESPONSES |
| US20210155933A1 (en) * | 2017-08-31 | 2021-05-27 | Gilead Sciences, Inc. | Tlr-9 agonists for modulation of tumor microenvironment |
| WO2020061129A1 (en) | 2018-09-19 | 2020-03-26 | President And Fellows Of Harvard College | Compositions and methods for labeling and modulation of cells in vitro and in vivo |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5683874A (en) * | 1991-03-27 | 1997-11-04 | Research Corporation Technologies, Inc. | Single-stranded circular oligonucleotides capable of forming a triplex with a target sequence |
| FR2814370B1 (fr) * | 2000-09-22 | 2004-08-20 | Centre Nat Rech Scient | Utilisation d'un complexe acide nucleique/pei pour le ciblage de cellules souches du cerveau |
| US8153141B2 (en) * | 2002-04-04 | 2012-04-10 | Coley Pharmaceutical Gmbh | Immunostimulatory G, U-containing oligoribonucleotides |
| TW200533750A (en) * | 2004-02-19 | 2005-10-16 | Coley Pharm Group Inc | Immunostimulatory viral RNA oligonucleotides |
| US20050197312A1 (en) * | 2004-03-03 | 2005-09-08 | Kevin Fitzgerald | Transcription factor RNA interference reagents and methods of use thereof |
| WO2006116458A2 (en) * | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhances immunostimulatory activity |
-
2006
- 2006-10-12 EA EA200801045A patent/EA200801045A1/ru unknown
- 2006-10-12 BR BRPI0617254-7A patent/BRPI0617254A2/pt not_active IP Right Cessation
- 2006-10-12 US US12/088,752 patent/US20090169472A1/en not_active Abandoned
- 2006-10-12 AU AU2006301230A patent/AU2006301230A1/en not_active Abandoned
- 2006-10-12 CA CA002625488A patent/CA2625488A1/en not_active Abandoned
- 2006-10-12 JP JP2008535031A patent/JP2009511034A/ja active Pending
- 2006-10-12 EP EP06807200A patent/EP1937812A2/en not_active Withdrawn
- 2006-10-12 WO PCT/EP2006/067334 patent/WO2007042554A2/en not_active Ceased
- 2006-10-12 KR KR1020087011347A patent/KR20080065656A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009511034A5 (enExample) | ||
| Kang et al. | Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges | |
| Le et al. | Nucleic acid-based technologies targeting coronaviruses | |
| US8389495B2 (en) | Olioodeoxynucleotide and its use to induce an immune response | |
| WO2001051500A1 (en) | Oligodeoxynucleotide and its use to induce an immune response | |
| TWI620568B (zh) | 用於治療ｂ型肝炎及ｄ型肝炎感染之方法 | |
| JP2004509970A5 (enExample) | ||
| CN109843902A (zh) | 用于B型肝炎病毒感染的RNAi剂 | |
| Sohrab et al. | Design and delivery of therapeutic siRNAs: application to MERS-coronavirus | |
| TW200412981A (en) | Immunostimulatory nucleic acids | |
| CN102762215A (zh) | Hbv反义抑制剂 | |
| JP2017538679A5 (enExample) | ||
| CA2752694A1 (en) | Synthetic rna-based agonists of tlr7 | |
| JP2002514397A5 (enExample) | ||
| Gupta et al. | A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases | |
| NO329492B1 (no) | Anvendelse av immunstimulerende oligodeoksynukleinsyremolekyler for fremstilling av immunstimulerende, farmasoytiske sammensetninger og farmasoytiske sammensetninger som inneholder de samme. | |
| WO2009004085A3 (en) | Dsrna for treating viral infection | |
| EP2943251B1 (en) | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response | |
| TW201923080A (zh) | 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子 | |
| KR20150016330A (ko) | 올리고뉴클레오타이드 킬레이트 복합체 방법 | |
| JP2009506122A5 (enExample) | ||
| Gao et al. | Designing a novel nano-vaccine against SARS-CoV-2 | |
| RU2014121304A (ru) | Ингибирование экспрессии вирусных генов | |
| Vasukutty et al. | Navigating Latency-Inducing Viral Infections: Therapeutic Targeting and Nanoparticle Utilization | |
| CA2379003A1 (en) | Therapy of respiratory influenza virus infection using free and liposome-encapsulated ribonucleotides |